Inhaled LPS challenge in healthy subjects: a dose escalation study Source: International Congress 2018 – Studies on the mechanisms underlying airway disease Year: 2018
Anti-IL17 treatment controls airway asthmatic responses exacerbated by LPS Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Effect of lipopolysaccharide (LPS) priming on Candida -induced acute lung injury (ALI) Source: Eur Respir J 2003; 22: Suppl. 45, 585s Year: 2003
Lipopolysaccharide (LPS) inhalation causes an increase in mucosal CD8+ve cells Source: Eur Respir J 2001; 18: Suppl. 33, 316s Year: 2001
Lipopolysaccharide challenge in healthy smokers Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010
Quantification of inflammatory cytokines in exhaled breath particles following segmental and inhalation endotoxin challenge of healthy volunteers Source: Virtual Congress 2021 – Deep phenotyping of obstructive diseases for precision medicine Year: 2021
Levels of IL-17 are increased in induced sputum of subjects with SAR after single nasal allergen challenge Source: Eur Respir J 2006; 28: Suppl. 50, 600s Year: 2006
Effects of acute and chronic LPS exposure on the inflammatory response in CF mice Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009
Lipopolysaccharide (LPS) inhalation causes an increase in activated neutrophils and lymphocytes Source: Eur Respir J 2001; 18: Suppl. 33, 108s Year: 2001
In COPD moxifloxacin enhances th1-immune response in the presence of bacterial endotoxin by inducing IL-2 expression Source: Annual Congress 2009 - Inflammatory cells and cytokines Year: 2009
Relationships of mannitol challenge to methacholine challenge and inflammatory markers in asthmatics receiving inhaled corticosteroids Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease Year: 2012
LPS induced airway inflammation in man Source: Annual Congress 2009 - Airway inflammation and host defence Year: 2009
Cytokines concentrations in induced sputum of mild COPD patients. Correlation to clinical response to inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 309s Year: 2002
Chronic LPS instillation model in mice: a useful model for emphysema studies? Source: Annual Congress 2005 - PG11 - Experimental models for COPD and asthma Year: 2005
Effect of inhaled SNG001 (interferon-beta 1a) on sputum and blood antiviral biomarkers following a respiratory virus infection in asthmatic subjects Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013
Genetic variation of mouse responses to intratracheal challenge with LPS: lung injury, hyperinflation, and inflammation Source: Eur Respir J 2005; 26: Suppl. 49, 559s Year: 2005
Combined treatment with fluticasone plus salmeterol protects against allergen induced asthmatic responses and subsequent increase in sputum eosinophils Source: Eur Respir J 2002; 20: Suppl. 38, 189s Year: 2002
Treatment: how does inflammatory phenotype influence response to treatment in airway disease? Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease Year: 2007
The anti-IL-17A-antibody secukinumab does not attenuate ozone induced acute airway neutrophilia in healthy volunteers Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments Year: 2012
Low dose inhaled LPS challenge – Reproducibility of the inflammatory response Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012